Simsek, E. T. Et Al. 2016. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9 , 810-816.

Simsek, E. T., EŞKAZAN, A. E., Cengiz, M., AR, M. C., EKİZOĞLU ERATAK, S., SALİHOĞLU, A., ... Gulturk, E.(2016). Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9, 810-816.

Simsek, Eda Et Al. "Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia," JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9, 810-816, 2016

Simsek, Eda T. Et Al. "Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia." JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9, pp.810-816, 2016

Simsek, E. T. Et Al. (2016) . "Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia." JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9, pp.810-816.

@article{article, author={Eda Tanrikulu Simsek Et Al. }, title={Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia}, journal={JOURNAL OF CLINICAL PATHOLOGY}, year=2016, pages={810-816} }